Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Hong Kong · Delayed Price · Currency is HKD 16.65
-0.12 (-0.72%)
Sep 10, 2026, 1:49 PM HKT
HKG:6826 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,275 | 10,169 | 13,346 | 17,596 | 16,428 | 23,247 | |
Market Cap Growth | -42.94% | -23.81% | -24.15% | 7.11% | -29.33% | 40.30% |
Enterprise Value | 5,193 | 8,073 | 11,268 | 15,426 | 13,661 | 20,392 |
Last Close Price | 16.77 | 23.07 | 24.17 | 25.07 | 22.61 | 30.87 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 21.97 | 36.40 | 29.83 | 38.38 | 80.52 | 53.77 |
Forward PE | - | 9.51 | 10.73 | 12.54 | 12.85 | 13.24 |
PS Ratio | 2.71 | 3.74 | 4.68 | 6.06 | 6.91 | 10.82 |
PB Ratio | 1.15 | 1.63 | 2.12 | 2.65 | 2.46 | 3.13 |
P/TBV Ratio | 1.39 | 1.93 | 2.73 | 3.43 | 3.24 | 4.04 |
P/FCF Ratio | 76.36 | 29.79 | 43.79 | 43.30 | - | 265.24 |
P/OCF Ratio | 19.94 | 18.61 | 19.34 | 25.17 | 62.83 | 55.33 |
PEG Ratio | - | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.94 | 2.97 | 3.95 | 5.31 | 5.75 | 9.49 |
EV/EBITDA Ratio | 13.47 | 17.35 | 19.29 | 24.77 | 35.23 | 50.04 |
EV/EBIT Ratio | 36.12 | 30.32 | 28.46 | 35.74 | 73.52 | 84.37 |
EV/FCF Ratio | 54.50 | 23.65 | 36.97 | 37.96 | - | 232.66 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.07 | 0.08 | 0.07 | 0.02 | 0.02 |
Debt / EBITDA Ratio | 1.33 | 0.90 | 0.78 | 0.69 | 0.32 | 0.30 |
Debt / FCF Ratio | 5.37 | 1.30 | 1.57 | 1.11 | - | 1.48 |
Net Debt / Equity Ratio | -0.36 | -0.39 | -0.39 | -0.39 | -0.41 | -0.46 |
Net Debt / EBITDA Ratio | -6.31 | -5.21 | -4.20 | -4.19 | -7.10 | -8.47 |
Net Debt / FCF Ratio | -23.73 | -7.10 | -8.05 | -6.42 | 31.28 | -39.41 |
Asset Turnover | 0.34 | 0.35 | 0.38 | 0.38 | 0.30 | 0.26 |
Inventory Turnover | 1.52 | 1.49 | 1.66 | 1.56 | 1.56 | 1.61 |
Quick Ratio | 2.85 | 3.12 | 3.56 | 4.35 | 5.76 | 6.78 |
Current Ratio | 3.49 | 3.79 | 4.22 | 5.24 | 6.91 | 7.62 |
Return on Equity (ROE) | 2.07% | 3.62% | 6.30% | 6.92% | 3.18% | 5.89% |
Return on Assets (ROA) | 1.13% | 2.16% | 3.27% | 3.50% | 1.48% | 1.86% |
Return on Invested Capital (ROIC) | 3.02% | 5.92% | 8.27% | 8.93% | 3.96% | 5.98% |
Return on Capital Employed (ROCE) | 2.20% | 4.10% | 5.90% | 6.10% | 2.60% | 3.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.42% | 2.75% | 3.35% | 2.60% | 1.24% | 1.86% |
FCF Yield | 1.31% | 3.36% | 2.28% | 2.31% | -0.54% | 0.38% |
Dividend Yield | 6.96% | 4.82% | 4.40% | 2.24% | 1.43% | 1.99% |
Payout Ratio | 172.07% | 91.13% | 61.80% | 16.46% | 67.54% | 24.96% |
Buyback Yield / Dilution | 0.59% | 0.56% | 1.77% | 30.24% | 1.46% | 0.62% |
Total Shareholder Return | 7.56% | 5.38% | 6.17% | 32.48% | 2.88% | 2.61% |